Showing results (21-30 of 365) with videos related to

Sort By:
Pageof 37
Cancer Treatment Reviews|April 26, 2020
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skippingRavi Salgia, Martin Sattler, Juergen Scheele, et al.
Current Opinion in Oncology|December 25, 2012
Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developmentsEnriqueta Felip, Alex Martinez-Marti, Pablo Martinez, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2014
Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?Pablo Martinez, Alex Martinez-Marti, Alejandro Navarro, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivorsErnest Nadal, Bartomeu Massuti, Manuel Dómine, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2011
Tissue sampling in lung cancer: a review in light of the MERIT experienceMartin Reck, Andreas Hermes, Eng-Huat Tan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 27, 2010
SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated editionJosé Manuel Trigo Pérez, Pilar Garrido López, Enriqueta Felip Font, et al.
Current Opinion in Oncology|February 8, 2006
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are goingRafael Rosell, Mauricio Cuello, Fabiana Cecere, et al.
Cancer Treatment Reviews|December 8, 2023
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancerFortunato Ciardiello, Fred R Hirsch, Robert Pirker, et al.
Clinical Lung Cancer|June 14, 2011
Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)Susana Cedrés, Isaac Nuñez, Marina Longo, et al.
Clinical Lung Cancer|February 25, 2016
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Benjamin Besse, Julie Renee Brahmer, et al.
Pageof 37